Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Pertussis infection in infants and children: Treatment and prevention

Sylvia Yeh, MD
Section Editor
Morven S Edwards, MD
Deputy Editor
Mary M Torchia, MD


The treatment and prevention of pertussis (whooping cough) infection in infants and children will be discussed here. The clinical presentation, including complications, and the diagnosis of pertussis in infants and children; the microbiology, epidemiology, and pathogenesis of pertussis infection; and the clinical features, treatment, and prevention of pertussis in adolescents and adults are discussed separately:

(See "Pertussis infection in infants and children: Clinical features and diagnosis".)

(See "Pertussis infection: Epidemiology, microbiology, and pathogenesis".)

(See "Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis".)

(See "Pertussis infection in adolescents and adults: Treatment and prevention".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jul 14, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Tiwari T, Murphy TV, Moran J, National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005; 54:1.
  2. American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.609.
  3. Halperin SA, Wang EE, Law B, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT). Clin Infect Dis 1999; 28:1238.
  4. Centers for Disease Control and Prevention (CDC). Pertussis--United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2005; 54:1283.
  5. Cherry JD, Harrison R, Bradley JS, et al. Pertussis in young infants -- Guidance for clinicians. May 2010, updated June 2011. www.cdph.ca.gov/HealthInfo/discond/Pages/Pertussis.aspx (Accessed on July 10, 2015).
  6. Wang K, Bettiol S, Thompson MJ, et al. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev 2014; :CD003257.
  7. Mertsola J, Viljanen MK, Ruuskanen O. Salbutamol in the treatment of whooping cough. Scand J Infect Dis 1986; 18:593.
  8. Krantz I, Norrby SR, Trollfors B. Salbutamol vs. placebo for treatment of pertussis. Pediatr Infect Dis 1985; 4:638.
  9. Roberts I, Gavin R, Lennon D. Randomized controlled trial of steroids in pertussis. Pediatr Infect Dis J 1992; 11:982.
  10. Zoumboulakis D, Anagnostakis D, Albanis V, Matsaniotis N. Steroids in treatment of pertussis. A controlled clinical trial. Arch Dis Child 1973; 48:51.
  11. Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children. Pediatr Infect Dis J 1995; 14:870.
  12. Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev 2007; :CD004404.
  13. Kwantes W, Joynson DH, Williams WO. Bordetella pertussis isolation in general practice: 1977-79 whooping cough epidemic in West Glamorgan. J Hyg (Lond) 1983; 90:149.
  14. Henry R, Dorman D, Skinner J, Mellis C. Limitations of erythromycin in whooping cough. Med J Aust 1981; 2:108.
  15. Riitta H. The effect of early erythromycin treatment on the infectiousness of whooping cough patients. Acta Paediatr Scand 1982; 298:10.
  16. Centers for Disease Control and Prevention (CDC). Pertussis--United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51:73.
  17. Centers for Disease Control and Prevention. Guidelines for the control of pertussis outbreaks. www.cdc.gov/pertussis/outbreaks/guide/index.html (Accessed on July 10, 2015).
  18. Hewlett EL, Edwards KM. Clinical practice. Pertussis--not just for kids. N Engl J Med 2005; 352:1215.
  19. Bass JW. Pertussis: current status of prevention and treatment. Pediatr Infect Dis 1985; 4:614.
  20. Hoppe JE. Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. The Erythromycin Study Group. Pediatr Infect Dis J 1992; 11:189.
  21. Bass JW, Klenk EL, Kotheimer JB, et al. Antimicrobial treatment of pertussis. J Pediatr 1969; 75:768.
  22. Steketee RW, Wassilak SG, Adkins WN Jr, et al. Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. J Infect Dis 1988; 157:434.
  23. Bergquist SO, Bernander S, Dahnsjö H, Sundelöf B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J 1987; 6:458.
  24. Tapiainen T, Aittoniemi J, Immonen J, et al. Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children. Acta Paediatr 2016; 105:39.
  25. Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. Lancet 1999; 354:2101.
  26. Centers for Disease Control and Prevention (CDC). Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin--Knoxville, Tennessee, 1999. MMWR Morb Mortal Wkly Rep 1999; 48:1117.
  27. Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in early infancy and pyloric stenosis. Pediatrics 2015; 135:483.
  28. Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 2001; 139:380.
  29. Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002; 156:647.
  30. Lund M, Pasternak B, Davidsen RB, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ 2014; 348:g1908.
  31. Hauben M, Amsden GW. The association of erythromycin and infantile hypertrophic pyloric stenosis: causal or coincidental? Drug Saf 2002; 25:929.
  32. Friedman DS, Curtis CR, Schauer SL, et al. Surveillance for transmission and antibiotic adverse events among neonates and adults exposed to a healthcare worker with pertussis. Infect Control Hosp Epidemiol 2004; 25:967.
  33. Langley JM, Halperin SA, Boucher FD, et al. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004; 114:e96.
  34. Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J 2001; 20:1149.
  35. Aoyama T, Sunakawa K, Iwata S, et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr 1996; 129:761.
  36. Baće A, Zrnić T, Begovac J, et al. Short-term treatment of pertussis with azithromycin in infants and young children. Eur J Clin Microbiol Infect Dis 1999; 18:296.
  37. Trollfors B. Effect of erythromycin and amoxycillin on Bordetella pertussis in the nasopharynx. Infection 1978; 6:228.
  38. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). MMWR Recomm Rep 1991; 40:1.
  39. Winter K, Zipprich J, Harriman K, et al. Risk Factors Associated With Infant Deaths From Pertussis: A Case-Control Study. Clin Infect Dis 2015; 61:1099.
  40. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18:326.
  41. Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008; 47:328.
  42. Mikelova LK, Halperin SA, Scheifele D, et al. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr 2003; 143:576.
  43. Pierce C, Klein N, Peters M. Is leukocytosis a predictor of mortality in severe pertussis infection? Intensive Care Med 2000; 26:1512.
  44. American Academy of Pediatrics. Pertussis in young infants. www.aap-ca.org/clinical/pertussis/pertussis_in_young_infants.html (Accessed on February 14, 2012).
  45. Rowlands HE, Goldman AP, Harrington K, et al. Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants. Pediatrics 2010; 126:e816.
  46. Romano MJ, Weber MD, Weisse ME, Siu BL. Pertussis pneumonia, hypoxemia, hyperleukocytosis, and pulmonary hypertension: improvement in oxygenation after a double volume exchange transfusion. Pediatrics 2004; 114:e264.
  47. Grzeszczak MJ, Churchwell KB, Edwards KM, Pietsch J. Leukopheresis therapy for severe infantile pertussis with myocardial and pulmonary failure. Pediatr Crit Care Med 2006; 7:580.
  48. Donoso AF, Cruces PI, Camacho JF, et al. Exchange transfusion to reverse severe pertussis-induced cardiogenic shock. Pediatr Infect Dis J 2006; 25:846.
  49. Nieves D, Bradley JS, Gargas J, et al. Exchange blood transfusion in the management of severe pertussis in young infants. Pediatr Infect Dis J 2013; 32:698.
  50. Halasa NB, Barr FE, Johnson JE, Edwards KM. Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? Pediatrics 2003; 112:1274.
  51. Murray EL, Nieves D, Bradley JS, et al. Characteristics of severe Bordetella pertussis infection among infants </= 90 days of age admitted to pediatric intensive care units – Southern California, September 2009 - June 2011. J Pediatric Infect Dis Soc 2013; 2:1.
  52. Kuperman A, Hoffmann Y, Glikman D, et al. Severe pertussis and hyperleukocytosis: is it time to change for exchange? Transfusion 2014; 54:1630.
  53. Chen HN, Lee ML, Tsao LY. Exchange transfusion using peripheral vessels is safe and effective in newborn infants. Pediatrics 2008; 122:e905.
  54. Dodhia H, Miller E. Review of the evidence for the use of erythromycin in the management of persons exposed to pertussis. Epidemiol Infect 1998; 120:143.
  55. De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J 1995; 14:969.
  56. Yeh SH. Pertussis: persistent pathogen, imperfect vaccines. Expert Rev Vaccines 2003; 2:113.
  57. Halperin SA, Bortolussi R, Langley JM, et al. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive bordetella pertussis infection. Pediatrics 1999; 104:e42.
  58. Knuf M, Schmitt HJ, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 2008; 152:655.
  59. Belloni C, De Silvestri A, Tinelli C, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003; 111:1042.
  60. Halasa NB, O'Shea A, Shi JR, et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 2008; 153:327.